Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | LTB4R2 | Q9NPC1 | 10/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149225 | 0.98 | TP53 (0.64) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL4155537 | 0.98 | TP53 (0.64) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL4159317 | 0.98 | TP53 (0.64) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL4153434 | 0.95 | TP53 (0.68) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL4167183 | 0.92 | TP53 (0.64) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL4170594 | 0.91 | NPC1 (0.65) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL4159010 | 0.91 | NPC1 (0.65) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL4161699 | 0.91 | NPC1 (0.65) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL2069520 | 0.90 | TP53 (0.70) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL29266757 | 0.89 | NPC1 (0.75) | TP53NPC1JAK2RAB9APAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | LABORATORIOS SALVAT, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | PPARG, PPARD, TYRO3 | TP53 1939/4885NPC1 3120/4885JAK2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.